Psychedelic Research & Clinical Trials
Sunstone is establishing the gold standard for psychedelic clinics to ensure that the delivery of psychedelic-assisted therapy is patient-centric, responsible, safe, and effective.
View All Trials
01
Sunstone designs and delivers innovative clinical trials with leading psychedelic drug developers and medical bodies.
- Beckley Psytech
- COMPASS Pathways
- Cybin
- Lykos Therapeutics
- MindMed
- Reunion Neuroscience
- Transcend Therapeutics
- Usona Institute
02
We work with a broad range of psychedelics.
- Psilocybin
- MDMA
- LSD
- 5-MeO-DMT
- Methylone
03
Across a wide array of clinical indications.
- Adjustment Disorder (AD)
- Demoralization in Patients with Cancer
- Palliative Care (End of Life)
- Generalized Anxiety Disorder (GAD)
- Major Depressive Disorder (MDD)
- Major Depressive Disorder in Patients with Cancer
- Post-Traumatic Stress Disorder (PTSD)
- Postpartum Depression
- Treatment-Resistant Depression (TRD)
04
In partnership with top-tier academic and medical institutions.
- Adventist HealthCare
- Dana-Farber Cancer Institute
- Johns Hopkins Center for Psychedelic & Consciousness Research
- McGill University
- Memorial Sloan Kettering Cancer Center
- The University of Vermont
Sunstone is Developing and Refining the Standards of Patient Care
Discover the Patient ExperienceIndustry Leadership: A Wide Breadth of Clinical Trials
![](https://www.sunstonetherapies.com/wp-content/themes/sunstone-therapies/images/infographic-divider.png)
05
Psychedelics
MDMA
Psilocybin
5-MeO-DMT
LSD
Methylone
08
Treatment Indications
PTSD (Post-Traumatic Stress Disorder)
Demoralization
Palliative Care (End of Life)
MDD (Major Depressive Disorder)
TRD (Treatment-Resistant Depression)
AD (Adjustment Disorder)
GAD (Generalized Anxiety Disorder)
Postpartum Depression
05
Active Trials in 2024
![](https://www.sunstonetherapies.com/wp-content/uploads/2024/03/AdobeStock_538222469-1-1-1024x683.jpeg)